DNA methylation profiling revealed MES subtype as the predominant molecular tumor subtype (37.4%), followed by RTK I (30.4%), RTK II (23.8%), and others (8.4%; MYCN, midline, H3 G34 mutant, H3 K27-altered). The gene discussed is MYCN; the disease is neoplasm.